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uNTRODUCTION
Dr. Tak Mak was this year’s honored E. Donnall
homas lecturer at the Tandem BMTMeetings, held
n February 1, 2003, in Keystone, Colorado. Dr. Mak
as contributed a cornerstone of immunology by elu-
idating the structure and organization of the T-cell
eceptor (TCR), a contribution of vital importance to
any, if not all, of us in this ﬁeld. His work now
xtends in exciting new directions involving signaling
athways in apoptosis. Dr. Mak is consistently iden-
iﬁed by Science Watch as one of the most cited
cientists in the world. He completed his undergrad-
ate studies at the University of Wisconsin in Madi-
on and obtained his PhD degree from the University
f Alberta. Currently, he is the director of the Ad-
anced Medical Discovery Institute in Toronto and is
senior scientist of the Ontario Cancer Institute.
uring his very distinguished career, Dr. Mak has
arnered many awards, including the Gairdner Inter-
ational Award and the General Motors Sloan Prize.
e is a member of the National Academy of Sciences,
rare distinction for non-Americans, and a Fellow of
he Royal Society. The following review is a modiﬁed
ranscribed version of the presentation made by Dr.
ak.
ECTURE
It is indeed an honor and a pleasure to be part of
his movement, this legacy of Dr. Thomas, who has c
B&MTade the transplantation of bone marrow possible and
hose contributions have mitigated disease in so many
ifferent health settings. I am humbly grateful to be
ncluded as a small part of this legacy. Today, I would
ike to share with you some of our thoughts on the
rocess of apoptosis and how it affects the way we
nderstand disease, especially cancer and autoimmune
isorders.
I have chosen the title “Apoptosis: ’Tis Death
hat Makes Life Live,” appropriating a phrase from a
houghtful poem by Robert Browning. He wrote:
You never know what life means till you die; even
hroughout life, ’tis death that makes life live, gives it
hatever the signiﬁcance.” As biologists, we can take
his concept, twist it slightly, and apply it literally
ather than philosophically. That is, without apopto-
is, a form of programmed cell death, there can be no
ormal life. In my talk, I will try to convince you of the
alidity of this borrowed notion.
Homeostasis, as we all know, is essential to the
hysiology of a multicellular organism. Cell growth
ust always be balanced by cell death or differentia-
ion. When this balance is missing, as when there is
ore cell death and differentiation than growth, then
egenerative diseases result. More importantly for this
articular audience, when there is excessive cell
rowth and not enough cell death or differentiation,
ancer and autoimmune diseases result. The cell death
nder discussion here is not the run-of-the-mill ne-Autoimmunity
oi:10.1016/S1083-8791(03)00215-5rosis that we are all familiar with (cell death charac-
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terized by the swelling of cytoplasm and mitochon-
dria). Some 20 years ago, the pathologist Andrew
Wiley noticed another form of cell death that looked
morphologically different under the microscope. To
describe what he saw, Wiley coined the term apoptosis
from the Greek word meaning “falling of the leaves.”
At the morphologic level, a hallmark of apoptosis is
the shrinking of the cytoplasm and condensation of
the nucleus. There are also very distinct differences
between apoptosis and necrosis at the biochemical and
physiological levels. For example, necrotic cell death
tends to affect a group of cells, such as when a tissue
is exposed to a cytotoxic cytokine. In contrast, apop-
tosis occurs at the level of the individual cell, and each
cell has to assess the stimulus and makes its own
decision about whether to die or survive. For example,
inﬂammation causes necrotic cell death, whereas
apoptotic cell death tends to be independent of in-
ﬂammatory responses. At the biochemical level, there
are even more dramatic differences between necrosis
and apoptosis. Necrotic cell death does not require
energy, whereas apoptosis does. Apoptosis also in-
volves cleaving the entire genome into short DNA
fragments of about 200 nucleotides in length, indicat-
ing that apoptosis is regulated by speciﬁc enzymatic
steps. This “laddering” of DNA might not affect
you as a healthy organism, but it keeps biochemists
employed in running tests to clearly establish that
apoptosis has occurred.
As well as being relevant for cancer and autoim-
mune diseases and, on the ﬂip side, for degenerative
diseases, apoptosis is very important for embryonic
development. In 1986 at MIT, Robert Horvitz recog-
nized that the intact function of at least 3 genes was
required for normal cell death and embryogenesis in
the worm Caenorhabditis elegans. Without these genes,
which are called ced-3, ced-4, and ced-9, apoptosis
cannot occur, and there is no development. So funda-
mental was this observation that Dr. Horvitz was
awarded the Nobel Prize for this work in 2002. Mam-
mals also require apoptosis for embryonic develop-
ment. Let me remind you of the 2 cell death pathways
that have been identiﬁed in animals. These are the
extrinsic and intrinsic pathways of apoptosis. The ex-
trinsic pathway is mediated by death receptors present
or induced on a cell’s surface. For example, when a T
cell expresses a trimer of Fas (CD95) on its surface and
it encounters a trimer of Fas ligand (FasL) expressed
on another cell’s surface, intracellular signals are
transduced within the T cell to recruit the down-
stream signaling proteins Fas-associated death domain
(FADD), caspase-8, and Casper (cﬂip). These proteins
initiate a cascade of signaling events that leads to the
cleavage of caspase-3 and, ultimately, programmed
cell death. However, signals through Fas that induce
cell death are always balanced by signals that promote
cell survival and inﬂammation. These signals are often
delivered via the binding of tumor necrosis factor
(TNF) to its receptors. Indeed, blocking the TNF
pathway has become a very successful way of treating
rheumatoid arthritis. In fact, TNF stimulation can
result in the delivery of signals leading to apoptosis as
well as survival, so that the balance of cell death/
survival in hematopoietic cells is maintained to a large
extent by the triggering of TNF receptors.
Our laboratory was very interested in looking at
this balance at the genetic level, and so Klaus Pfeffer
knocked out the Tnfr1 gene in mice and showed that
this receptor can indeed mediate both cell death and
cell survival. Similar studies were done by Shigekzu
Nagata and Peter Krammer, who were the ﬁrst to
deﬁne the roles of FasL and Fas; this was seminal work
that demonstrated the importance of the Fas receptor.
We extended their ﬁndings downstream of Fas and
investigated the transducers FADD, Casper, and
caspase-8. Once Fas has bound to FasL, the FADD
protein is recruited to the cytoplasmic portion of Fas.
FADD in turn recruits caspase-8, a caspase that acti-
vates the caspase cascade leading to apoptosis. FADD
also recruits Casper. It was still not known whether
Casper acts to promote or oppose cell death. Wen-
Chen Yeh in my laboratory knocked out the FADD
and Casper genes, as well as the TNF receptor–asso-
ciated factor 2 (TRAF2) gene that acts downstream of
TNFR, in an attempt to dissect these pathways. He
found that TRAF2 indeed mediates cell survival,
whereas FADD function promotes cell death. Curi-
ously, Casper turned out to be a protein opposing cell
death because, in the absence of Casper, a signal ini-
tiated by the binding of FasL or TNF to their respec-
tive receptors resulted in increased apoptosis. This
work has given us a better understanding at the ge-
netic level of how Fas and TNF signals are trans-
duced, what downstream signals work to promote
apoptosis, and how these are balanced by signals
blocking cell death.
One of the surprises we encountered during these
studies was that neither the FADD nor Casper knock-
out mice survived beyond early embryogenesis. We
had thought that Fas signaling was involved only in
hematopoietic cell death and survival, processes that
occur long after the development of fundamental em-
bryonic structures. However, it turns out that the
FADD and Casper genes are ﬁrst used early during
embryogenesis for the development of the myocar-
dium. In the absence of either FADD or Casper, the
mice die with malformations of the heart. David
Wallach then demonstrated a similar phenotype for
the caspase-8 knock-out mouse. We came to the con-
clusion that the whole molecular cascade downstream
of Fas engagement, which was evolutionarily designed
for the much earlier process of myocardium develop-
ment, had been appropriated to mediate cell death and
survival in the later-developing hematopoietic cells.
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Perhaps this type of phenomenon explains why mam-
mals have so few genes. Those developmental genes
that are no longer required once an organ has devel-
oped may be “borrowed” by the immune system to
implement homeostasis. We have seen this type of
“borrowing” before. Before our investigations of
FADD, Jose De la Pompa and Hiroaki Takimoto in
my laboratory knocked out the gene encoding cyto-
plasmic nuclear factor of activated T cells (NFATc), a
transcription factor acting downstream of the TCR.
The NFATc knock-out mice did not survive because
of defective fetal cardiac valve formation. In other
words, NFATc, an essential gene for cardiac valve
formation, was ultimately hijacked for use in TCR
signaling. So what is the lesson of these stories? The
lesson is that our genes are multifunctional, assuming
different roles once their functions during embryo-
genesis are completed. The number of genes we have
to carry within our genomes is thus decreased, mini-
mizing the mistakes that can be made during DNA
replication.
Now let us turn to the intrinsic pathway of
apoptosis, which occurs when a signal triggered by
events such as radiation, stress, or chemotherapy leads
to activation of the tumor suppressor gene p53. In some
mysterious way, p53 sends a signal to mitochondria to
say that it has received a signal for the cell to die. The
mitochondria respond by releasing cytochrome c into
the cytoplasm, which in turn causes the recruitment of
a protein called apoptotic protease activating factor-1
(Apaf1). Interestingly, the Apaf1 gene is the homolog
of the ced-4 gene that Bob Horvitz described 15 years
ago. In mammals, Apaf1 recruits pro–caspase-9,
which then cleaves itself to generate active caspase-9.
Active caspase-9 in turn cleaves pro–caspase-3 to ac-
tivate this enzyme, and active caspase-3 triggers an
enzymatic cascade that induces apoptosis. Our labo-
ratory decided to genetically dissect the intrinsic path-
way to determine the precise roles of cytochrome c,
Apaf1, caspase-9, and caspase-3 in apoptosis.
If you knock out the cytochrome c gene in a
mouse, the animal dies on the eighth day of gestation
because cytochrome c is required for electron trans-
port in the mitochondria. To obtain a live mouse for
study, we “knocked in” a mutation of the cytochrome
c gene that allows the protein to function for electron
transport but does not permit it to induce apoptosis.
Some of the mice with the knock-in cytochrome c
mutation died just before birth with ectopic protru-
sions of the brain. We believe that a lack of apoptosis
led to an accumulation of brain cells, overall swelling
of the brain, and death. Again we see this multifunc-
tionalism: a protein required for normal cellular me-
tabolism is also essential for normal neuronal apopto-
sis. Again we are reminded of Browning’s words: when
there is no cell death, there is no life.
When Hiroki Yoshida in my laboratory generated
Apaf1 knock-out mice and analyzed them, he found
that Apaf1 is an essential player in the intrinsic path-
way of apoptosis but that cell death in response to
prolonged TCR signaling was completely intact. This
was the ﬁrst demonstration that the extrinsic pathway
is completely capable of doing its job without the
function of Apaf1-mediated intrinsic pathway. This
ﬁnding also implied that the intrinsic pathway could
likely do its job without Fas or other death-receptor
killing. Thus, we have 2 pathways of apoptosis, inde-
pendently dedicated to dealing death to individual
cells so that the whole organism may live.
I would now like to turn to the way we understand
cancer, and for this audience, I have chosen to talk
about lymphomas. When lymphomas do not die,
there is no life for the patient. We know that cancer is
a complex disease, with contributions coming from
mutations in genes governing the cell cycle, growth
receptors, differentiation, DNA repair, and cell death.
For the purposes of this talk, I am going to focus on
the concept of defective cell death. Cancer is a mul-
tistage disease, and cancerous clones are continually
selected at each stage. For a long time, we have been
brainwashed into thinking that this selection process
favors genetic and epigenetic changes that enhance
cell proliferation. However, results obtained over the
last few years have forced us to realize that clones are
concomitantly selected for survival. A paradoxical re-
sult coming from the work of Gerard Evans and
Chuck Sherr is that a particular tumour clone may
proliferate but may not survive. We are talking here of
a cancer that has the curious property of oncogene-
induced apoptosis. We are all used to thinking of an
oncogene as a gene that induces the proliferation of
cells and thus leads to cancer; few of us suspected that
an oncogene could induce apoptosis. However, if the
oncogene Ras is transfected into a cell culture, the ﬁrst
thing you see is massive cell death. Only after this
event is a clone selected that can survive in culture.
Now, as biologists, we never used to care about the
ﬁrst few weeks of transfected cell culture, as long as a
transformed cell came out at the end. We did not
realize that in normal cells, the deregulation of cell-
cycle progression or proliferation can actually trigger
apoptosis. We now know that radiation and chemo-
therapeutic agents induce intrinsic apoptosis, a pro-
cess in which p53 plays a very important role. How
does this happen in a cancer cell? A cancer cell un-
dergoes mutations in both the genes that restrain cell
growth and the genes that promote apoptosis. In par-
ticular, cancer cells losing function of p53 experience
uncontrolled proliferation and suppressed apoptosis.
To demonstrate the importance of p53 to apopto-
sis, about 2 or 3 years ago we undertook a simple
experiment in collaboration with Scott Lowe. We
introduced a gene encoding a temperature-sensitive
mutation of p53 into p53-deﬁcient cells. At 39°C, the
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mutated temperature-sensitive p53 protein cannot
fold normally, and the cells proliferate madly. How-
ever, if you move that ﬂask of cells to another incu-
bator at 33°C, in a few minutes the temperature-
sensitive p53 folds like wild-type p53, and massive cell
death is subsequently induced. The condensation of
the chromatin is clear, marking this death as apopto-
tic. In contrast, if you introduce the temperature-
sensitive p53 gene into a cell lacking Apaf1 or
caspase-9 and incubate at 33°C, there is little cell
death. These data tell us that p53-induced cell death
follows the intrinsic pathway and that p53-mediated
apoptosis is crucial for preventing cancer.
Next, I’m going to describe work in our laboratory
investigating 2 kinds of lymphomas and how cell-
survival pathways affect the patient’s disease. First, I
will talk about Hodgkin lymphoma (HL; which is
older than everybody in the audience, including me).
HL was ﬁrst described as a clinical entity by Thomas
Hodgkin in 1832. The unusual multinucleated Reed-
Sternberg (RS) cells characteristic of HL were then
described by Sternberg in 1898 and Reed in 1902.
Despite this early start, the molecular pathogenesis of
HL continued to elude delineation. Researchers
studying HL were able to describe the disease on a
biochemical level, but the molecular mechanisms driv-
ing the cancer remained a mystery. We know that
most HL affects younger people and that these pa-
tients experience fever, weight loss, and night sweats.
These observations do not tell you very much except
that a lot of cytokines are involved in producing the
clinical symptoms. However, another interesting fea-
ture of HL is that Hodgkin nodes need to grow
adjacent to each other. So, perhaps among the cyto-
kines produced is a growth factor that is needed for
the spreading of the tumor.
As you know, cytokines are involved in immune
responses, leading us to the interesting part of this
story. HL patients have reduced cell-mediated im-
mune responses, but their humoral responses are en-
hanced. In addition, the clinical symptom of pruritus
common in HL patients suggests the presence of im-
munoglobulin (Ig)E. Moreover, RS cells stain posi-
tively for the immunological marker CD30. Taken
together, these results suggested that some kind of
cytokine imbalance was occurring and that RS cells
might be affected in some way by the surrounding
lymphocytes. When Ursula Kapp, a hematologist
from Freiburg, was in my laboratory, we had the idea
that there might be a deviation toward T-helper type
2 (Th2) immune responses in HL. As you know,
T cells can differentiate into 2 helper subsets: Th1
cells, primarily involved in cell-mediated immune re-
sponses; or Th2 cells, primarily involved in humoral
responses. Because HL patients have abnormal hu-
moral responses, we investigated whether Th2 cyto-
kines were overexpressed, either by RS cells in an
autocrine fashion or by the surrounding lymphocytes
in a paracrine fashion. We tested these possibilities by
using DNA microarray experiments, and to make a
very long story very short, the answer to the HL
mystery is interleukin (IL)-13. When we ﬁrst exam-
ined the 3 RS cell lines available, the only Th2 cyto-
kine that was consistently overexpressed was IL-13. In
contrast, IL-4, IL-5, and granulocyte-macrophage
colony-stimulating factor were sometimes elevated
but sometimes not. In non-HL cell lines and in cells
transformed by Epstein-Barr virus, there was no IL-13
expression.
So what is IL-13? IL-13 acts on B cells to induce
proliferation and immunoglobulin class switching, es-
pecially to IgE. IL-13 is also thought to be important
for protection against parasites common in central
Africa or certain parts of Asia, because this cytokine
promotes monocyte and eosinophil activation and the
development of ﬁbrosis. Ursula’s work was then ex-
tended by Brian Skinnider, a hematopathologist who
joined my laboratory to carry out what seemed an
interesting task: to obtain as many sections of HL
tissue as possible and look for the presence of IL-13.
He found that IL-13 is indeed secreted by patient
samples and by many HL cell lines. He also looked for
expression of the IL-13R1 chain, which combines
with the IL-4R chain to make up the IL-13 receptor.
When IL-13 engages IL-13R, the intracellular signal
transducer JAK1 phosphorylates IL-4–induced signal
transducer and activator of transcription-6 (STAT6)
to give activated phospho-STAT6 (P-STAT6). Luck-
ily, an antibody was available that binds speciﬁcally to
the tyrosine 641 residue of STAT6, but only when it
is phosphorylated. Using immunostaining techniques,
Brian was able to demonstrate that IL-13 was engag-
ing IL-13R on RS cells and that the IL-13R was being
produced by both the RS cells and the surrounding T
lymphocytes. Moreover, using the anti–P-STAT6 an-
tibody, Brian showed that, in every patient sample, RS
cells were replete with P-STAT6, indicating stimula-
tion. Even in the 5 RS cell lines that we were able to
assay, we found clearly positive P-STAT6 signals. We
then looked at different types of lymphomas. Almost
all nodular sclerosing HL samples examined were pos-
itive for IL-13, IL-13R1, and P-STAT6 but negative
for IL-4. Sections of HLs with lymphocyte-predom-
inant histology, which are not considered classic HLs,
showed no staining for IL-13, IL-13R1, or
P-STAT6. In B-cell non-HL, a rare case might se-
crete IL-13, but no T-cell non-HLs did. Although
these results seemed very clear, we were cautious and
considered the possibility of redundancy among
STATs and other cytokines. We were also a bit puz-
zled because IL-13 is not known to be a transforming
cytokine, and, unlike STAT3, STAT6 is not a known
transforming signal. Brian then compared the staining
patterns of STAT6 with those for STAT3 and
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STAT4. Overall, we found P-STAT6 in about 80% of
HL samples. The reason why the value is not 100% is
that we have included many lymphocyte-depleted and
mixed cellularity HL cases, which are only about 50%
to 70% P-STAT6 positive. P-STAT6 staining in nod-
ular sclerosing HL is almost 100%. However, we were
surprised to ﬁnd that many HL samples were also
positive for P-STAT3. We still do not know whether
IL-13 or another cytokine is directly or indirectly
activating STAT3 or how this event might contribute
to the transformation process.
How do we know that IL-13 is really affecting
tumor cell growth in HL? When HL cell lines are
grown in culture without IL-13 (eg, when anti–IL-13
neutralizing antibodies are added), both the HL cell
lines HDLM-2 and L-1236 stop growing. However, 2
other HL cell lines that produce a large amount of
IL-13 do not stop growing when anti–IL-13 antibody
is added, perhaps because of the comparatively large
amounts of the cytokine that cannot be completely
sopped up. If you remove IL-13 from L-1236, it even
undergoes apoptosis. This result suggests that the cells
are dying because they lack cell division and survival
signals as a consequence of IL-13 depletion.
There are currently no animal models for HL.
The closest we can come is to grow HL cell lines in
nonobese diabetic/severe combined immunodeﬁcient
mice. A human HL tumor can grow in these mutant
animals, and when you examine sections of these tu-
mors, you see CD30 staining. Moreover, instead of
the very sparse RS cell distribution in HL tumors in
humans, there are wall-to-wall RS cells in the manip-
ulated mice, and tissue sections stain very strongly for
P-STAT6 and IL-13. We have also charted the
growth of these tumors in the presence of anti–IL-13.
We postulate that, when IL-13 engages the IL-13
receptor, some mediator must also activate the tran-
scription factor nuclear factor-B (NF-B), which can
activate TNF- transcription and secretion. TNF-
could then come back to the same cell and act on its
TNF receptors to promote tumor cell survival. To
test this hypothesis, we blocked IL-13 from binding to
HDLM-2 cells and looked for downstream conse-
quences. We found that TNF- production was
downregulated and that NF-B signaling was abol-
ished. So, we think that several molecular loops are
interacting: everybody will be happy because every-
body’s data are integrated in this scheme. First, IL-13
activates the IL-13 receptor on HL cells, which acti-
vates STAT6, which cross-talks to the NF-B signal-
ing pathway, which promotes survival. NF-B can
also be activated through CD30 signaling, perhaps
induced via engagement by the CD30 receptor ex-
pressed on eosinophils. CD40 on RS cells might also
be engaged by CD40 ligand expressed on Th2 cells,
also leading to NF-B activation. In any case, the end
result appears to be the production of TNF-alpha,
which engages the TNF receptor and activates cell
survival and cell proliferation. In the Epstein-Barr
virus–positive H-RS cells, LMP1 may also activate
NF-B.
Finally, I’m going to discuss some relatively re-
cently described lymphomas: the mucosa-associated
lymphoid tissue, or MALT, lymphomas. MALT lym-
phomas were ﬁrst recognized by Wright and Isaacson
in London, England, in the mid 1980s. These re-
searchers noticed that there were similarities among
lymphomas isolated from the intestine and the stom-
ach. One of the interesting things that uniﬁes all
MALT lymphomas is that they occur at sites of
chronic infections or inﬂammation. Wright and Isaac-
son suggested that, even though these cancers were
extranodal and in different locations, they shared a
common molecular pathogenesis.
Isaacson conceived a brilliant scheme for the de-
velopment of MALT lymphomas which has proved
true at every step so far. He postulated that a gastric
MALT lymphoma is initiated by the presence of the
Helicobacter pylori bacterium, which activates B cells
with the help of T cells. As a result of this activation,
B cells proliferate. During the early stages of the
disease, B-cell proliferation is completely dependent
on the dose of H pylori antigens, and patients can be
“cured” with antibiotics effective against H pylori. In a
Lancet article about 2 years ago, Isaacson showed that
the patients who no longer fully responded to antibi-
otics were often those whose tumor cells contained 1
of 2 chromosomal translocations. One of these trans-
locations moves the 1p22 chromosomal region to
chromosome 14, where the immunoglobulin heavy
chain gene is located. This positioning activates a gene
called BCL10, which is located at 1p22. In this situa-
tion, antibiotics can no longer repress B-cell prolifer-
ation, and the patients can go on to develop high-
grade lymphomas.
When BCL10 was cloned and analyzed by Martin
Dyer and another group, the gene, at ﬁrst glance,
appeared to be involved in apoptosis. BCL10 has a
caspase recruitment domain (CARD), and other genes
with CARDs interact with proteins that can recruit
the caspases that induce and execute apoptosis. This
situation is reminiscent of APAF1, mutations of which
occur in melanomas. The Apaf1 protein isolated from
melanoma patients has a truncated or mutated C ter-
minus, leading researchers to suspect that it can no
longer induce apoptosis and block melanoma devel-
opment. Similarly, wild-type BCL10 transfected into
normal cells resulted in apoptosis, but transfection of
mutant BCL10 isolated from MALT lymphoma pa-
tients did not. However, our work with BCL10 has
conﬁrmed that you cannot jump to conclusions on the
basis of overexpression experiments. Jurgen Ruland, a
hematologist in the laboratory, asked a very simple
question: “What happens when the Bcl10 gene is
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knocked out? If this gene truly encodes a tumor sup-
pressor and is involved in apoptosis, as are Apaf1,
caspase-9 and caspase-3, then knocking it out should
lead to less apoptosis.” However, one third of
Bcl10/ mice died early during embryogenesis be-
cause the neural tube did not close. Furthermore,
when Jurgen examined sections of Bcl10/ brain, he
found more apoptosis rather than less. Thus, rather
than being involved in cell death, Bcl10 appeared to be
required for cell survival.
To resolve this apparent paradox, Jurgen and his
colleague Gordon Duncan did 6 more months of work
and accumulated hundreds of data points. They were
forced to conclude that there were no differences in
apoptosis in any Bcl10/ tissue, regardless of stimuli.
However, they made 2 very interesting observations.
The serum immunoglobulin level in Bcl10/ mice
was reduced 10- to 100-fold, and although T and B
cells developed normally in the absence of Bcl10, they
could not be activated. In particular, the T cells in the
Bcl10 knock-outs did not secrete IL-2 or upregulate
the IL-2R chain. The answer was glaring at us as
immunologists. The production of IL-2 and cellular
responses to IL-2 require the cooperation of the tran-
scription factors NFAT, NF-B, and adaptor protein 1
(AP-1), so Bcl10 must be functioning in one of the
pathways leading to the activation of IL-2. Intensive
biochemical study showed that activation of the TCR
itself was normal, as was activation of Ras, extracellu-
lar regulated kinase (ERK), and AP-1. The nuclear
factor of activated T cells (NF-AT)/calcineurin path-
way was also normal. It turns out that the defective
signaling in Bcl10/ mice is due to speciﬁc blockage
of the pathway leading from antigen receptor engage-
ment to NF-B activation. Antigen receptor–induced
AP-1 activation was intact, and lymphocyte stimula-
tion by phorbol myristate acetate (PMA) (which by-
passes the TCR) or lipopolysaccharide (which by-
passes the B-cell receptor) was normal. Activation of
NF-B by TNF- or IL-1 was also normal. In short,
Bcl10 is a gene that operates in the black hole between
the protein kinase Cs and NF-B, upstream of IB D
kinase (IKK) activation. Moreover, this pathway is
unique to antigen receptor signaling because stimula-
tion of the lipopolysaccharide receptor, TNF recep-
tor, or IL-1 receptor did not require (or bypassed)
Bcl10. As a result of these ﬁndings, we believe that
Bcl10 is not a tumor suppressor gene. Rather, the
translocation of Bcl10 in MALT lymphomas leads to
excessive activation of NF-B activation, which drives
cell survival.
The other gene activated by translocation in
MALT lymphomas, MALT1, has an interesting struc-
ture. MALT1 contains a caspase-like domain, a death
domain, and 2 immunoglobulin-like domains. Muta-
tions of the caspase-like domain had already been
shown to reduce NF-B activation. Jurgen Ruland
extended these ﬁndings to show that MALT1 acts
downstream of Bcl10. He transfected Bcl10/ cells
with the MALT1 gene and demonstrated that antigen
receptor–speciﬁc NF-B activation was restored.
When he knocked out MALT1 in mice, the animals
had virtually the same phenotype as Bcl10 knock-outs.
His work showed that MALT1 acts downstream of
Bcl10 and is an essential participant in T-cell activa-
tion. What genes act upstream of MALT1? Jurgen
next transfected a gene called BIMP (also CARD11 or
CARMA) into Bcl10/ cells and showed that NF-B
activation could not occur. So, within a period of 2
years, Jurgen was able to establish a signaling pathway
leading from protein kinase C to BIMP to Bcl10 to
MALT1 to NF-B activation. The important message
from this work is that NF-B is involved not only in
inﬂammation, stress responses, and the development
of lymphoid organ structures, hematopoietic cells,
keratinocytes, and neuronal synapses, but also in neo-
plasia, cell survival, and the control of apoptosis.
So, I hope I have convinced you that it is not just
philosophically that “’tis death that makes life live.”
From a biologist’s point of view, cell death is just as
essential as survival. In fact, apoptosis may be the
default pathway of cell fate, and a cell will naturally die
unless it receives a survival signal.
I would like to conclude by thanking the individ-
uals who made this talk possible: Jose de la Pompa for
the NFATc work; Hiroki Yoshida, who worked on
Apaf1; Razq Hakem and Minna Woo, who investi-
gated caspases-3 and -9; and Wen Chen Yeh, who
deciphered the roles of TRAF2, FADD, and Casper.
Our collaborator Scott Lowe did much of the early
work. For the HL studies, the role of IL-13 was
deﬁned by Ursula Kapp and Brian Skinnider, with the
cooperation and collaboration of Randy Gascoyne in
Vancouver and Bruce Patterson in Toronto. Jurgen
Ruland did most of the work on the Bcl10 and
MALT1 knock-outs with the help of Gordon Duncan,
Pam Ohashi of the Ontario Cancer Institute, and
Gabrielle Nunez in Michigan.
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